Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LHLWT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LR-DM1
|
|||||
| Synonyms |
LR DM1
Click to Show/Hide
|
|||||
| Organization |
Chinese Academy of Medical Science and Peking Union Medical College
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.6
|
|||||
| Structure |
|
|||||
| Antibody Name |
LR004
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Emtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.